DATA Globaldata Plc

RNS Number:6880A
Provalis PLC
12 July 2004


For Immediate Release                                            12th July 2004


                     Trading update for Financial Year 2004

G5 now branded as in2it(TM) and to be unveiled at the Diabetes Educators Meeting 
                        in Indianapolis in mid-August

Provalis plc (LSE: PRO; NASDAQ:PVLS), the Medical Diagnostics and
Pharmaceuticals Group, is pleased to announce that its unaudited results for the
financial year ended 30th June 2004 are in line with market expectations with:-

* Unaudited Group sales of #12.9m;

* Pharmaceutical sales 5 per cent ahead of last year at #11.4m;

* Medical Diagnostics sales of Glycosal(R) improving in the second half of
  the year, with the business achieving annual sales of #1.5m; and

* Net cash of #1.8m at 30th June 2004, with an unused bank facility of
  up to #3.0m.

Pharmaceutical Developments

The profitable Pharmaceuticals business continues to pursue a number of
development projects, particularly the acquisition of further products and the
enhancement of margins on its current product range. Preparations are already
underway for the launch of Erdotin(R), its new mucolytic, onto the UK and Ireland
markets early in 2005.

in2it(TM) Chosen as the Brand Name for Provalis' G5 Diagnostic Platform

Preparations for the launch of Provalis' in2it(TM) A1c(previously code named 
G5), our new 'point of care' diabetes management system, in Autumn 2004 continue
following the filing of the regulatory dossier in the USA in mid-June. Interest
in the product is exceeding our expectations, with our in-house US sales force
already receiving enquiries from a number of health management organisations and
distributors.

in2it(TM) A1c is to be formally unveiled at the American Diabetes Educators 
Meeting in Indianapolis in mid August.

Phil Gould, Chief Executive of Provalis, commented, "We are pleased that the 2nd
half of the year has seen stronger Group sales. In addition, completion of
in2it(TM) A1c (the brand name for G5), our new diabetes management system, and its
filing with the US FDA, were significant developments for the Group. The
projected Autumn launch of in2it(TM) A1c in the US, using our own direct sales
force, is the next important milestone in developing a branded point of care
diagnostics business focused on chronic disease."


                                      END

Provalis' Internet Website ; http://www.provalis.com

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of
1995: Statements in this announcement that relate to future plans, expectations,
events, performances and the like are forward-looking statements as defined in
the US Private Securities Litigation Reform Act of 1995. Actual results of
events could differ materially from those described in the forward-looking
statements due to a variety of factors. Such factors include, among others: the
viability of the Group's products, which are at various stages of development;
the generation of sufficient operating cash flow by the Group's pharmaceutical
and medical diagnostic businesses to finance the ongoing development of these
businesses as well as the Group's research and development activities; the
success of the Group's research and development strategy and activities;
uncertainties related to future clinical trial results and the associated
regulatory process; the execution and success of collaborative agreements with
third parties; availability and level of reimbursement for the Group's products
from government health administration authorities or other third-party payors;
the rate of net cash utilisation within the Group and, hence, the Group's
possible need for additional capital in the short, medium and/or long term; the
Group's intellectual property position and the success of patent applications
for its products and technologies; the Group's dependence on key personnel;
general business and economic conditions; the impact of future laws, regulations
and policies; stock market trends in the Group's sector; and other factors
beyond the Group's control that may cause the Group's available capital
resources to be used more quickly than expected. These and other factors that
could affect the Company's future results are more fully described in its
filings with the US Securities and Exchange Commission, in particular the latest
20-F filing, copies of which are available from the Company Secretary at the
Company's registered address.

For further information:-

Dr Phil Gould, Chief Executive Officer, Provalis plc, Tel: 01244 833463
Mr Peter Bream, Finance Director, Provalis plc, Tel: 01244 833552
Mr Lee Greenbury, Company Secretary, Provalis plc, Tel: 01244 833402
Lisa Baderoon, Buchanan Communications, Tel: 020 7466 5000


Notes to Editors

Provalis plc (LSE: PRO; NASDAQ: PVLS) is a diversified healthcare group with two
operating businesses:-

* Medical Diagnostics - develops and sells to world markets
medical diagnostic products for chronic disease management. The business'
principal products are currently Glycosal(R) and Osteosal(R) in the areas of
diabetes and osteoporosis respectively, with in2it(TM) A1c, the business' next
generation diabetes management system, on schedule for launch in Autumn 2004.

* Pharmaceuticals - sells and markets its own, and third party,
branded, prescription medicines in the UK and Ireland to GPs and hospitals
through its own regionally managed sales force. The business' principal product
is Diclomax(R), a medicine for use in the treatment of musculo-skeletal 
disorders, and it also sells products in the areas of gastroenterology, 
osteoporosis, migraine and dermatology.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
TSTEADXNESSLEFE

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Août 2023 à Août 2024